Press Release – Page 5 – I-Mab | Pioneering the Next Generation of Immuno-Oncology

2023.03.07

I-Mab Receives “A” Rating in Updated MSCI ESG Assessment

2022.11.03

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

2022.10.05

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

2022.09.13

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

2022.09.10

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

2022.09.06

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

2022.08.30

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

2022.08.23

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

2022.08.19

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

2022.07.22

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China